Reinnervate Ltd and Roslin Cellab collaborate on the development of protocols for three dimensional growth of hESCs
Prof Stefan Przyborski, CSO and founder of Reinnervate Ltd, commented: ‘It is well known that the physical environment in which cells grow plays an important role in controlling cell differentiation and the development of functioning tissues. Current two dimensional (2D) models restrict the growth potential of differentiating stem cells. The culture of cells in three dimensions (3D) radically enhances cell growth, differentiation and function. At Reinnervate, we have developed Alvetex®Scaffold which provides a solution for simple and routine 3D cell culture. In this collaboration, we are combining the advantages of 3D cell growth with the enormous potential of hESCs. Preliminary work has already demonstrated enhanced neural development by stem cells using Alvetex®Scaffold technology. We are now engaged in more extensive investigations to fully exploit 3D cell differentiation by hESCs in collaboration with Roslin Cell Lab.’
Jason King, Manager of Business Development at Roslin Cellab said ‘we are seeing great demand for improved 3D culture systems. Stem cell scientists can use these to study the biology of the stem cell “niche”. This is the 3D microenvironment in which stem cells normally reside until they receive signals that cause them to start dividing and to move out into the organ to differentiate into cells of the required type (eg. heart, brain or liver cells) and repair tissue damage. As a company we have a strong interest in liver cells (hepatocytes) which we can make from our stem cell lines. It is known that when hepatocytes are grown in 3D structures, they have both better metabolic enzyme activity and extended life spans, which are both great advantages when using these cells in cell-based toxicity assays.’
As part of the collaboration, Reinnervate will supply its market leading Alvetex®Scaffold technology and general expertise in the 3D growth of cells in vitro. Roslin Cellab will supply cells, expertise and protocol development capabilities to the project.
Financial terms were not disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.